Cushing Syndrome Is Associated with Worse Survival and Higher Morbidity in Neuroendocrine Neoplasms

Clicks: 6
ID: 322569
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #31 of 359 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Ectopic Cushing syndrome (ECS) is a severe paraneoplastic complication of neuroendocrine neoplasms (NENs), but its association with survival and clinically relevant outcomes remains insufficiently defined in matched real-world cohorts. OBJECTIVE: To assess the association of code-defined Cushing syndrome compatible with ECS with OS and clinical outcomes in patients with NENs using a large propensity score-matched cohort. DESIGN: Retrospective cohort study with 1:1 propensity score matching. SETTING: Electronic medical records from TriNetX Global Collaborative Network, a federated database aggregating clinical data from international healthcare organizations. PATIENTS: Adult patients (≥18 years) with NEN (n = 105,854), including 265 in the ECS-compatible cohort. After matching, 264 patients in the ECS-compatible cohort were compared with 264 patients without documented Cushing syndrome. MAIN OUTCOME MEASURES: Primary outcome was OS. Secondary outcomes included hospitalization, emergency care use, severe infections, venous thromboembolism, metabolic complications, organ failure, and metastatic progression. RESULTS: ECS was associated with significantly reduced OS compared with non-ECS patients (8-year survival: 55.3% vs 71.2%; hazard ratio [HR] 1.848 [95% confidence interval 1.348-2.534]; P < 0.001). ECS patients had increased risks of hospitalization, severe infections, venous thromboembolism, and metabolic complications including hypertension, diabetes mellitus, and hypokalemia, as well as organ failure (kidney and liver failure). No significant increase in metastatic progression was observed. CONCLUSIONS: ECS-compatible Cushing syndrome was associated with worse survival and substantially higher morbidity in patients with NENs, mainly reflected by hypercortisolism-related complications rather than tumor progression. Early recognition and treatment of hypercortisolism may be critical to improve outcomes.
Reference Key
openalex_W7170157460 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Max Kappenstein, Anna Franziska Hamm, Emilie Lehmler, Christine Koch, Daniel Groener, J Bojunga, Nikolas von Bubnoff, Viktoria Florentine Koehler
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag294
URL
https://doi.org/10.1210/clinem/dgag294
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.